The PPARγ Agonist Efatutazone Increases the Spectrum of Well-Differentiated Mammary Cancer Subtypes Initiated by Loss of Full-Length BRCA1 in Association with TP53 Haploinsufficiency

Peroxisome proliferator–activated receptor gamma (PPARγ) agonists have anticancer activity and influence cell differentiation. We examined the impact of the selective PPARγ agonist efatutazone on mammary cancer pathogenesis in a mouse model of BRCA1 mutation. Mice with conditional loss of full-lengt...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Nakles, Rebecca E., Kallakury, Bhaskar V.S., Furth, Priscilla A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Investigative Pathology 2013
Témata:
Short Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3668033/
https://ncbi.nlm.nih.gov/pubmed/23664366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajpath.2013.02.006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky